Diaceutics PLC Issue of Share Options (9131R)
July 03 2020 - 1:00AM
UK Regulatory
TIDMDXRX
RNS Number : 9131R
Diaceutics PLC
03 July 2020
Diaceutics PLC
("Diaceutics" or the "Company")
Issue of Share Options
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation
company, announces the issue of share options over ordinary shares
of 0.2p each in the Company ("Share Options") on 30 June 2020, to
certain members of the Company's senior management team and other
key staff. These share options have been issued pursuant to certain
contractual share-based entitlements in place prior to the IPO and
are governed by the rules of the Company's Employee Share Option
Plan ("ESOP").
Share Options were granted as follows:
Name Number of Share Total no. of ordinary % of existing
Options granted shares under option issued share capital
post grant
Damian Thornton (COO and
PDMR) 4,200 102,704 0.12%
---------------- --------------------- ---------------------
Jordan Clark (CTO and
PDMR) 4,200 76,114 0.09%
---------------- --------------------- ---------------------
Susanne Munksted (CPO
and PDMR) 4,200 70,672 0.08%
---------------- --------------------- ---------------------
A further 214,500 Share Options were granted to 51 employees,
each of whom received 4,200 Share Options.
The Share Options vest in full after three years following date
of grant. The exercise price of the Share Options is 0.2p per share
being the nominal value of the share.
Following the grant the total number of share options
outstanding granted to the Company's Directors, senior management
team and key employees is 1,790,762, representing approximately
2.13% of the Company's current issued share capital of
84,068,923.
Enquiries:
Diaceutics PLC www.diaceutics.com
Peter Keeling, Chief Executive via Walbrook PR
Officer
Philip White, Chief Financial
Officer
Cenkos Securities plc (Nominated adviser
and broker) +44 (0)207 397 8900
Callum Davidson / Giles
Balleny
Michael Johnson (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
At Diaceutics we believe that every patient should get the
precision medicine they deserve. We are a data analytics and
end-to-end services provider enabled by DXRX - the world's first
Diagnostic Network solution for the development and
commercialisation of precision medicine diagnostics. The Company
has worked on every precision medicine brought to market and
provides services to 36 of the world's leading pharmaceutical
companies. We have built the world's largest repository of
diagnostic testing data with a growing network of 2500 labs in 51
countries.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- ---------------------------------------------------------------------------------------
a. Name Damian Thornton
------------------------------------------------
2 Reason for notification
------------------------------------- ------------------------------------------------
a. Position/Status Chief Operating Officer
------------------------------------- ------------------------------------------------
b. Initial notification/ Initial
Amendment
------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- ---------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- ------------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- ------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 4,200
---------------------------------------------------------------------- ---------------
e. Date of the transaction 30 June 2020
------------------------------------- ------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- ------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- ---------------------------------------------------------------------------------------
a. Name Jordan Clark
------------------------------------------------
2 Reason for notification
------------------------------------- ------------------------------------------------
a. Position/Status Chief Technology Officer
------------------------------------- ------------------------------------------------
b. Initial notification/ Initial
Amendment
------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- ---------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- ------------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- ------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 4,200
---------------------------------------------------------------------- ---------------
e. Date of the transaction 30 June 2020
------------------------------------- ------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- ------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- ---------------------------------------------------------------------------------------
a. Name Susanne Munksted
------------------------------------------------
2 Reason for notification
------------------------------------- ------------------------------------------------
a. Position/Status Chief Precision Officer
------------------------------------- ------------------------------------------------
b. Initial notification/ Initial
Amendment
------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
-------------------------------------
b. LEI 213800VEWQBB39ZB8J81
------------------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- ---------------------------------------------------------------------------------------
a. Description of Options over new ordinary shares of 0.2
the financial p each
instrument, type
of instrument ISIN: GB00BJQTGV64
Identification
Code
------------------------------------- ------------------------------------------------
b. Nature of the Grant of share options
transaction
------------------------------------- ------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
------------------------------------- --------------------------
Exercise price
of 0.2p per
share 4,200
---------------------------------------------------------------------- ---------------
e. Date of the transaction 30 June 2020
------------------------------------- ------------------------------------------------
f. Place of the transaction Outside a trading venue
------------------------------------- ------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHMZGGNVZDGGZM
(END) Dow Jones Newswires
July 03, 2020 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024
